Illustrative image – not actual.Fresenius Kabi, a 100 per cent subsidiary of German healthcare group Fresenius, plans to invest approximately Rs.190 crore over the next two to three years in the active pharmaceutical ingredient (API) plant of the company.
The investments will go primarily into doubling production capacity of Dabur Pharma's active pharmaceutical ingredients (API) manufacturing facility in Kolkata.
The company is also working on increasing the business of Dabur Pharma to regulated markets such as Europe and North America. It would also work for getting approval from the US Food and Drug Administration for the Indian firm's formulation facility in Baddi, Himachal Pradesh.
To expand Dabur's business, Fresenius will work to seek necessary approvals from Food & Drug Administration for the domestic pharma company's newly commissioned formulation unit in Himachal Pradesh. The plant has already got approvals from Europe.
